Calidi's $5.2M Offering Adds Dilution Overhang to Cash Burn

Calidi Biotherapeutics (NYSE: CLDI) reported a first-quarter GAAP loss of $0.43 per share. The update landed alongside a $5.2 million underwritten public offering, shifting the investment case from pure clinical speculation to a financing-driven dilution calculus.

Cash Position and the $5.2M Equity Raise

The company held $6.6 million in cash and $0.2 million in restricted cash as of March 31, 2026. That compares to $5.6 million in cash and $0.2 million restricted at December 31, 2025. The $1 million sequential increase in unrestricted cash does not reflect the $5.2 million offering, which was priced after the quarter closed. The modest cash build likely came from warrant exercises or other non-operational inflows, because the GAAP loss implies ongoing cash consumption.

• Q1 GAAP EPS: -$0.43
• Cash and restricted cash: $6.8 million total ($6.6 million unrestricted)
• Post-quarter offering: $5.2 million in stock and pre-funded warrants

The post-quarter offering will add roughly $5.2 million before underwriting discounts and expenses. For a pre-revenue biotechnology firm, that sum extends the cash runway by perhaps one to two quarters, depending on the burn rate. The trade-off is immediate dilution. The offering includes common stock and pre-funded warrants, a structure that often signals urgency to close and a limited pool of institutional demand willing to take unrestricted shares at the market price. Existing shareholders absorb the dilution without any new clinical data to offset the share count increase.

The offering follows a prior announcement of a planned public offering of stock and pre-funded warrants, which had already pressured shares. That pattern reinforces the market's perception that Calidi must tap public markets repeatedly to fund operations.